⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

October 1, 2017Advances in TherapyOpen Access

Challenges Associated with Estimating Utility in Wet Age-Related Macular Degeneration: A Novel Regression Analysis to Capture the Bilateral Nature of the Disease

Robert Hodgson Timothy Reason David Trueman Rose Wickstead J. Kusel Adam Jasilek Lindsay Claxton Matthew Taylor Ruth Pulikottil-Jacob

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Novartis Pharmaceuticals UK Limited.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hodgson et al. (2017) studied this question.

synapsesocial.com/papers/69d97d015e5bcb4e3b836cd5 https://doi.org/10.1007/s12325-017-0620-x

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Quality of life in age-related macular degeneration: a review of the literaturePrognostic Study · 2006 · 312 citations
2Evidence-based medicine, utilities, and quality of lifeCost-Effectiveness Analysis · 1999 · 100 citations
3The Impact of Age-Related Macular Degeneration on Health Status Utility ValuesCross-Sectional Study · 2005 · 150 citations
4Patient and Public Preferences for Health States Associated with AMDOriginal Research · 2013 · 23 citations
5Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degenerationOriginal Research · 2007 · 19 citations
6Simulation contact lenses for AMD health state utility values in NICE appraisals: a different realityOriginal Research · 2014 · 21 citations
7Improved Vision-Related Function After Ranibizumab vs Photodynamic TherapyRCT · 2009 · 97 citations
8Improved Vision-Related Function After Ranibizumab Treatment of Neovascular Age-Related Macular DegenerationRCT · 2007 · 241 citations
9Measuring the Effect of Amphetamine Extended-Release (DYANAVEL® XR) on Driving Performance in Young Adult Drivers with ADHD Using a Sophisticated Driving SimulationAdvances in Therapy · 2026
10Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting AnalysisAdvances in Therapy · 2026

More from Advances in Therapy

More from University of York

More from Novartis (United Kingdom)

More from Leeds and York Partnership NHS Foundation Trust

More from CACI International (United Kingdom)

More from Costello Medical Consulting (United Kingdom)